Contemporary Management of Lower Urinary Tract Disease With Botulinum Toxin A: A Systematic Review of Botox (OnabotulinumtoxinA) and Dysport (AbobotulinumtoxinA)

Mangera, Altaf; Andersson, Karl‐Erik; Apostolidis, Apostolos; Chapple, Christopher R.; Dasgupta, Prokar; Giannantoni, Antonella; Gravas, Stavros; Madersbacher, Stephan

doi:10.1016/j.eururo.2011.07.001

Cited by 189 publications

(132 citation statements)

References 73 publications

Supporting

Mentioning

120

Contrasting

Unclassified

Order By: Relevance

“…These interactions between BONT-A and oral antimuscarinic agents have not been investigated deeply so far, and could be the object of future research. 17 In particular, it could be interesting to evaluate whether the intervals between BONT-A administrations could be increased by the use of antimuscarinic drugs and, eventually, the economic impact of this adjuvant therapy.…”

Section: Discussionmentioning

confidence: 99%

The use of oxybutynin in patients treated by means of botulinum neurotoxin A for neurogenic detrusor overactivity: an observational study

et al. 2013

View full text Add to dashboard Cite

Study design: This is an observational prospective noncontrolled study. We enrolled 105 patients affected by neurogenic detrusor overactivity (NDO) who underwent botulinum neurotoxin A (BONT-A) intradetrusor injection and were followed-up for 270 days. Objectives: To investigate the use of oxybutynin after BONT-A administration in NDO patients. Setting: Careggi University Hospital in Florence and Tor Vergata University Hospital in Rome. Methods: Prospective data from two Italian centers were collected in 1 year. Patients showing limited efficacy but good tolerability and adherence to oxybutynin 5 mg t.i.d. (three times a day). were enrolled in the study. Patients received BONT-A intradetrusor injection (onabotulinumtoxinA, 300 U) with a trigone-sparing technique, and the use of oxybutynin was registered at every visit. Results: 105 patients were included. At visit 1, only 30 patients (28.6%) used oxybutynin t.i.d., whereas 47 (45,2%) used a lower dosage and 28 (26.7%) stopped the therapy. At visit 2, 77.3% of patients who had reduced oxybutynin intake, maintained the dosage decided at visit 1. At visit 3, 51.9% returned to oxybutynin t.i.d.; 44.8% were on a reduced dosage and only 3 (2.9%) were not taking the drug. At visit 4, only 37.5% of patients were taking less than oxybutynin t.i.d. Conclusion: This study provides some important insights on the use of oral antimuscarinics in patients treated by means of BONT-A intradetrusor administration for NDO; in particular, it suggests that, after an initial reduction in the use of oxybutynin, patients tend to increase the dosage of this drug during the follow-up after the BONT-A treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

The use of oxybutynin in patients treated by means of botulinum neurotoxin A for neurogenic detrusor overactivity: an observational study

et al. 2013

View full text Add to dashboard Cite

show abstract

“…Since then, several observational studies have confirmed the significant and impressive response to BTX-A injections in the NB population (12)(13)(14). However, the current status of this mode of therapy is primarily limited to end-stage bladders as an option to delay bladder augmentation.…”

Section: Botulinum Toxinmentioning

confidence: 99%

Early experimental results of using a novel delivery carrier, hyaluronan-phosphatidylethanolamine (HA-PE), which may allow simple bladder instillation of botulinum toxin A as effectively as direct detrusor muscle injection

Shatoury

DeYoung

Turley

et al. 2018

Journal of Pediatric Urology

View full text Add to dashboard Cite

Early experimental results of using a novel delivery carrier, Hyaluronan-phosphatidylethanolamine (HA-PE) which may allow simple bladder instillation of Botulinum Toxin A as effectively as direct detrusor muscle injection. Abstract Intra-detrusor Botulinum Toxin-A (BTX-A) injection is the gold standard treatment for detrusor overactivity in clinical practice when medical treatment fails. Despite satisfactory results of BTX-A injection, the endoscopic procedure still has risks of anaesthetic and operative complications. Several studies have investigated more simple ways to deliver BTX-A to the detrusor muscle but with limited success. In our study, we assessed the evidence of BTX-A delivery using a newly modulated hyaluronan-phosphatidylethanolamine (HA-PE) carrier in a rat model through BTX-A-HA-PE bladder instillations. We used histological evidence of SNAP-25 protein cleavage and detection of Alexa Fluor®594-labelled BTX-A as a proof of physical BTX-A delivery across the urothelium. In addition, we assessed the functional impact of using HA-PE on rat detrusor muscle through urodynamic assessment both at baseline and 2 weeks later after 1% acetic acid instillation. We found positive histological evidence of SNAP-25 cleavage, detection of Alexa Fluor®594-BTX-A red fluorescence in bladder tissue supporting that HA-PE may be an efficient carrier to deliver BTX-A across the urothelium. Mohamed G. El Shatoury

show abstract

“…With such diverse etiologies for bladder dysfunction and a large demand (over 50 million people are estimated to have some type of urinary incontinence), many different classes of drugs have been investigated for symptomatic relief. Antimuscarinic drugs (e.g., oxybutynin, tolterodine, solifenacin, darifenacin) are now the first-line therapy for treatment of detrusor overactivity and the overactive bladder syndrome, but lower urinary tract symptoms can also be treated with, e.g., a-adrenoreceptor (AR) blockers alone or in combination with antimuscarinics or with onobotulinum toxin A (Andersson et al, 2009;Mangera et al, 2011).…”

Section: A Bladder Diseasementioning

confidence: 99%

The Pharmacology of Regenerative Medicine

et al. 2013

Self Cite

View full text Add to dashboard Cite

Contemporary Management of Lower Urinary Tract Disease With Botulinum Toxin A: A Systematic Review of Botox (OnabotulinumtoxinA) and Dysport (AbobotulinumtoxinA)

Cited by 189 publications

References 73 publications

The use of oxybutynin in patients treated by means of botulinum neurotoxin A for neurogenic detrusor overactivity: an observational study

The use of oxybutynin in patients treated by means of botulinum neurotoxin A for neurogenic detrusor overactivity: an observational study

Early experimental results of using a novel delivery carrier, hyaluronan-phosphatidylethanolamine (HA-PE), which may allow simple bladder instillation of botulinum toxin A as effectively as direct detrusor muscle injection

The Pharmacology of Regenerative Medicine

Contact Info

Product

Resources

About